Feature | May 16, 2013

Nearly 50 Percent of Patients With Cardiac Device Infections Don’t Survive Beyond Three Years

New study of Medicare patients presented at 2013 Heart Rhythm Society Meeting

May 16, 2013 — The incremental mortality in implantable pacemaker and defibrillator recipients who experience a device infection, compared to patients without device infection, is substantial and persists for at least three years after index hospitalization with infection. These are the key findings of a retrospective cohort study of 200,219 Medicare fee-for-service patients undergoing cardiac device procedures, with and without infection, that were presented today by M. Rizwan Sohail, M.D., a researcher from the Mayo Clinic divisions of infectious diseases and cardiovascular diseases, at Heart Rhythm 2013, the Heart Rhythm Society’s 34th Annual Scientific Sessions.

Previously, Sohail and his collaborators have reported that patients with cardiac device infections experience a two-fold increase in the mortality rate one year after device implantation, compared to patients without an infection. In this new study, Sohail and collaborators looked at the long-term mortality three years after the device procedure in 200,219 Medicare beneficiaries that underwent permanent pacemaker and defibrillator procedures between Jan. 1, 2007 and Dec. 31, 2007, including 5,817 patients with cardiac device infections.

Key findings of the study included:

  • The 15-29 percent higher mortality seen in patients with cardiac device infections, compared to patients without cardiac device infections, continued for at least three years.
  • Three years after the procedure:
    • Patients with pacemakers (PM) infection had 54 percent mortality, vs. 33 percent without PM infection (P<0.001)
    • Patients with ICD infection had 48 percent mortality vs. 32 percent without ICD infection (P<0.001)
    • Patients with CRT-D infections had a 51 percent mortality vs. 37 percent without CRT-D infection (p<0.001)
  • For PM patients with a device infection, the incremental mortality associated with device infection continues to increase for at least three years.

“It is well known that cardiac device therapies such as pacemakers, implanted cardioverter-defibrillators (ICDs), and cardiac resynchronization therapy/defibrillators (CRT-Ds) can reduce morbidity and mortality in appropriately selected patients,” said Sohail, “Unfortunately, these benefits can be significantly reduced, if the implantation/replacement procedure is complicated by a device infection. The focus of this study was to better understand the long-term mortality associated with CIED infections, stratified for different cardiac device types.”

This study was funded by Tyrx Inc., maker of implantable combination drug/device products focused on infection control for implantable electrophysiology devices.

For more information: www.HeartDeviceInfection.com

Related Content

Biotronik Launchs His-Bundle Pacing Tools
News | Pacemakers | June 16, 2020
June 16, 2020 - Biotronik has today announced its commitment to giving physicians additional tools to pace in the His
Videos | Pacemakers | February 13, 2020
This video illustrates how the Micra AV leadless pacemaker is delivered via catheter and enables atrioventricular (AV
The Micra AV leadless pacemaker
News | Pacemakers | February 13, 2020
February 13, 2020 — The U.S.
Results from the MARVEL 2 (Micra Atrial Tracking Using A Ventricular accELerometer) study shows that an investigational set of algorithms in the Medtronic Micra Transcatheter Pacing System (TPS) significantly improves synchrony and cardiac function in patients with atrioventricular (AV) block. This is an impaired electrical conduction between the chambers of the heart.
News | Pacemakers | November 15, 2019
(February 2020 update — the results of this trial led to the FDA clearnace of the Micra AV device in January 2020
Co-principal investigator professor Aydin Babakhani at the UCLA Integrated Sensor Laboratory holds an earlier version of the prototype leadless, wireless amnd batteryless pacemaker. Photo Credit: Cody Duty, Texas Medical Center.

Co-principal investigator professor Aydin Babakhani at the UCLA Integrated Sensor Laboratory holds an earlier version of the prototype leadless, wireless and battery-less pacemaker. Photo Credit: Cody Duty, Texas Medical Center.

News | Pacemakers | November 13, 2019
FDA Warns of Premature Battery Depletion in Some Medtronic Pacemakers
News | Pacemakers | May 07, 2019 | Dave Fornell, Editor
The U.S. Food and Drug Administration (FDA) issued a safety communication to alert healthcare providers and patients...
Artificial Intelligence Can Improve Emergency X-ray Identification of Pacemakers
News | Pacemakers | March 29, 2019
A research team from Imperial College London believes a new software could speed up the diagnosis and treatment of...
Medtronic Recalls Dual Chamber Pacemakers
News | Pacemakers | February 20, 2019
Medtronic is recalling its dual chamber implantable pulse generators (IPGs) due to the possibility of a software error...
CHLA/USC Team Designs Novel Micropacemaker

Model of the human heart with microprocessor located in the pericardial sac and attached to the left ventricle. Graphic courtesy of Business Wire.

News | Pacemakers | June 29, 2018
Investigators at Children's Hospital Los Angeles (CHLA) and the University of Southern California (USC) have...
Permanent Pacing Effective for Older Patients With Syncope and Bifascicular Block
News | Pacemakers | May 24, 2018
Syncope with bifascicular block may be caused by intermittent complete heart block, but competing diagnoses may coexist...